Health Topics — Neurological
When You Get Migraines — What the Research Shows
For the person with frequent migraines who has heard that cannabinoids might help and wants an honest account of what the science has actually found — including one specific finding about migraineurs specifically.
Migraine is not a headache that is worse than usual. It is a neurological event — a cascade that takes over the body for hours or days, with pain that can be disabling, alongside nausea, sensitivity to light and sound, and often an aftermath that leaves you depleted for another day beyond the attack itself. If you have migraines, you already know this. What you may not know is that there is a specific biological finding about people with chronic migraine that makes the cannabinoid research more directly relevant here than in most health conditions.
In 2007, researchers measured the cerebrospinal fluid — the fluid surrounding the brain and spinal cord — of people with chronic migraine and of healthy controls. They found that people with chronic migraine had anandamide levels 45% lower than those without migraine. Anandamide is the body's primary endocannabinoid — the compound the body makes itself to activate the same receptors that CBD and CBG interact with. Lower anandamide means a less well-regulated endocannabinoid system, particularly in the pain modulation pathways that migraine exploits.
This finding matters because it is specific. It is not a general correlation between cannabinoid use and headache relief. It is a direct measurement of a biological deficit in people with chronic migraine, taken from the fluid closest to the brain. Researcher Ethan Russo had proposed in 2004 — before this finding — that chronic migraine might reflect chronically low endocannabinoid tone. The CSF measurement was the most direct evidence yet that the hypothesis was tracking something real.
What the research has found — and the critical distinction
In 2024, the first placebo-controlled clinical trial of cannabis for acute migraine was completed and presented at the American Headache Society Annual Meeting. It found that vaporized cannabis reduced acute migraine pain compared to placebo. This is meaningful progress — migraine is one of the few neurological conditions where a cannabinoid clinical trial has now produced positive results in a controlled setting.
The critical distinction for anyone considering a hemp preparation: the trial used vaporized cannabis containing significant THC — not hemp-derived CBD or CBG. Earlier animal research suggests CBD and THC together are more effective than either alone for migraine-like symptoms. The human evidence that exists involves the full cannabis plant including THC, which hemp preparations do not contain.
This does not mean hemp preparations are irrelevant in migraine. CBD inhibits FAAH — the enzyme that breaks down anandamide. If depleted anandamide is part of what makes someone vulnerable to more frequent and more severe migraines, then supporting anandamide levels through FAAH inhibition is a mechanistically coherent approach. The step from that mechanism to a clinical benefit in migraine has not been tested in a controlled trial with hemp-derived CBD. It is the most scientifically motivated question in this area that remains unanswered.
Why stress matters for migraineurs specifically
Stress is among the most commonly reported migraine triggers. The biology explains why. Chronic stress depletes endocannabinoid tone — raising cortisol, activating the HPA axis, and reducing anandamide availability over time. For someone who may already have lower baseline anandamide than the average person, chronic stress is a direct assault on the regulatory buffer that helps maintain the pain threshold above migraine territory.
This is where CBG's stress research connects most directly to migraine. Not as a migraine treatment — but as something that addresses one of the primary biological drivers of migraine vulnerability. A person with chronic migraine who is also under sustained stress is losing endocannabinoid tone through two simultaneous channels: the baseline deficit the CSF data suggests, and the additional depletion that chronic stress produces. Supporting the stress response through CBG's documented mechanism is the most coherent entry point available from what hemp preparations actually contain.
On migraines and clinical care
Migraine is a neurological condition with established treatment options — both acute medications and preventive therapies — that have clinical trial evidence behind them. A neurologist specialising in headache disorders can assess which options are appropriate for the frequency and severity of your migraines. Nothing in this article suggests that cannabinoid preparations replace or substitute for appropriate migraine care.
If you are considering a CBD preparation alongside your current migraine management, the drug interaction consideration is relevant: several common migraine medications and preventive therapies are metabolised by CYP450 enzymes. Check with your prescribing neurologist or pharmacist before combining.
The migraine research is among the most compelling in this archive — a specific biological finding in human migraineurs, a completed clinical trial with positive results, and a mechanistic case for hemp-derived CBD that is coherent even though the controlled trial to confirm it hasn't been done. The research is developing faster in this area than in most. We will update this article as it does.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.